JCO Article Insights: Adoption of Capivasertib in Metastatic Hormone Receptor–Positive, HER2-Negative Breast Cancer – Efficacy, Toxicity and Treatment Sequencing

<p>In this JCO Article Insights episode, Giselle de Souza Carvalho provides a summary on  "<a href= "https://ascopubs.org/doi/10.1200/JCO-24-01295" target="_blank" rel="noopener">Navigating Treatment Pathways in Metastatic Hormone Receptor–Positive, HER2-Negative Breast Cancer: Optimizing Second-Line Endocrine and Targeted Therapies</a>" by Bhardwarj, et al and "<a href="https://ascopubs.org/doi/10.1200/JCO.24.00427" target="_blank" rel="noopener">US Food and Drug Administration Approval Summary: Capivasertib With Fulvestrant for Hormone Receptor–Positive, Human Epidermal Growth Factor Receptor 2–Negative Locally Advanced or Metastatic Breast Cancer With PIK3CA/AKT1/PTEN Alterations</a>" by Dilawari et al published in the Journal of Clinical Oncology. </p> <p><span style= "text-decoration: underline;"><strong>TRANSCRIPT</strong></span></p> <p dir="ltr">Giselle Carvalho: Hello and welcome to <a href= "https://ascopubs.org/journal/jco/podcast">JCO Article Insights</a> episode for the Dec...